BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35389830)

  • 1. Omarigliptin alleviates cognitive dysfunction in Streptozotocin-induced diabetic mouse.
    Li X; Yin Y; Li W; Li S; Zhang D; Liu Z
    Bioengineered; 2022 Apr; 13(4):9387-9396. PubMed ID: 35389830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIRT3 ameliorates diabetes-associated cognitive dysfunction via regulating mitochondria-associated ER membranes.
    Chang Y; Wang C; Zhu J; Zheng S; Sun S; Wu Y; Jiang X; Li L; Ma R; Li G
    J Transl Med; 2023 Jul; 21(1):494. PubMed ID: 37481555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
    Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
    Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
    Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
    J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation.
    Song S; Ding Y; Dai GL; Zhang Y; Xu MT; Shen JR; Chen TT; Chen Y; Meng GL
    Acta Pharmacol Sin; 2021 Feb; 42(2):230-241. PubMed ID: 32770173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells.
    Li L; Qian K; Sun Y; Zhao Y; Zhou Y; Xue Y; Hong X
    Bioengineered; 2021 Dec; 12(1):4805-4815. PubMed ID: 34338149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omarigliptin for the treatment of type 2 diabetes.
    Tan X
    Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Atageldiyeva KK; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Diabetologia; 2016 Mar; 59(3):533-41. PubMed ID: 26693710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
    Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
    Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omarigliptin for the treatment of type 2 diabetes mellitus.
    Evans PM; Bain SC
    Expert Opin Pharmacother; 2016 Oct; 17(14):1947-52. PubMed ID: 27466703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omarigliptin protects against nonalcoholic fatty liver disease by ameliorating oxidative stress and inflammation.
    Li Z; Wang H; Wu K; Zhang L
    J Biochem Mol Toxicol; 2021 Dec; 35(12):e22914. PubMed ID: 34533252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
    Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effect of formononetin on cognitive impairment in streptozotocin (STZ)-induced diabetic mice.
    Wang J; Wang L; Zhou J; Qin A; Chen Z
    Biomed Pharmacother; 2018 Oct; 106():1250-1257. PubMed ID: 30119194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
    Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
    Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling.
    Yu L; Gong B; Duan W; Fan C; Zhang J; Li Z; Xue X; Xu Y; Meng D; Li B; Zhang M; Bin Zhang ; Jin Z; Yu S; Yang Y; Wang H
    Sci Rep; 2017 Jan; 7():41337. PubMed ID: 28120943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydromyricetin Improves Endothelial Dysfunction in Diabetic Mice via Oxidative Stress Inhibition in a SIRT3-Dependent Manner.
    Hua YY; Zhang Y; Gong WW; Ding Y; Shen JR; Li H; Chen Y; Meng GL
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albiflorin alleviates cognitive dysfunction in STZ-induced rats.
    Ma X; Song M; Yan Y; Ren G; Hou J; Qin G; Wang W; Li Z
    Aging (Albany NY); 2021 Jul; 13(14):18287-18297. PubMed ID: 34319254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mangiferin alleviates diabetic pulmonary fibrosis in mice via inhibiting endothelial-mesenchymal transition through AMPK/FoxO3/SIRT3 axis.
    Fu TL; Li GR; Li DH; He RY; Liu BH; Xiong R; Xu CZ; Lu ZL; Song CK; Qiu HL; Wang WJ; Zou SS; Yi K; Li N; Geng Q
    Acta Pharmacol Sin; 2024 May; 45(5):1002-1018. PubMed ID: 38225395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis.
    Yan W; Pang M; Yu Y; Gou X; Si P; Zhawatibai A; Zhang Y; Zhang M; Guo T; Yi X; Chen L
    Life Sci; 2019 Aug; 231():116566. PubMed ID: 31201846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
    Biftu T; Sinha-Roy R; Chen P; Qian X; Feng D; Kuethe JT; Scapin G; Gao YD; Yan Y; Krueger D; Bak A; Eiermann G; He J; Cox J; Hicks J; Lyons K; He H; Salituro G; Tong S; Patel S; Doss G; Petrov A; Wu J; Xu SS; Sewall C; Zhang X; Zhang B; Thornberry NA; Weber AE
    J Med Chem; 2014 Apr; 57(8):3205-12. PubMed ID: 24660890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.